Phospho-AKT1/AKT2/AKT3 (Tyr315/316/312) Antibody
-
中文名称:磷酸化-AKT1/AKT2/AKT3 (Tyr315/316/312)兔多克隆抗体
-
货号:CSB-PA569237
-
规格:¥2454
-
图片:
-
Western blot analysis of extracts from HepG2 cells untreated or treated with EGF using AKT1/AKT2/AKT3(phospho-Tyr315/316/312) Antibody.
-
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using AKT1/AKT2/AKT3(Phospho-Tyr315/316/312) Antibody(left) or the same antibody preincubated with blocking peptide(right).
-
Immunofluorescence staining of methanol-fixed Hela cells using AKT1/AKT2/AKT3(phospho-Tyr315/316/312) Antibody.
-
Western blot analysis of extracts from 3T3 cells, treated with EGF or calf intestinal phosphatase (CIP), using AKT1/AKT2/AKT3 (phospho-Tyr315/316/312) Antibody.
-
-
其他:
产品详情
-
Uniprot No.:P31749 P31751 Q9Y243
-
宿主:Rabbit
-
反应种属:Human,Mouse,Rat
-
免疫原:Peptide sequence around phosphorylation site of tyrosine 315/316/312 (P-E-Y(p)-L-A) derived from Human AKT1/AKT2/AKT3.
-
免疫原种属:Homo sapiens (Human)
-
克隆类型:Polyclonal
-
纯化方式:Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
-
浓度:It differs from different batches. Please contact us to confirm it.
-
产品提供形式:Liquid
-
应用范围:ELISA,WB,IHC,IF
-
推荐稀释比:
Application Recommended Dilution WB 1:500-1:1000 IHC 1:50-1:100 IF 1:100-1:200 -
Protocols:
-
储存条件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
货期:Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
相关产品
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-